Safety evaluation study for patients with polycythemia vera

Phase 1

Recruiting

• Conditions: Polycythemia Vera; Myeloproliferative Neoplasms

• Registration Number: JPRN-jRCT2051210083
• Lead Sponsor: Ito Tomoki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

1. Confirmed diagnosis of PV according to either the 2008 or 2016 WHO classification criteria
2. PV patients being only treated with phlebotomy and the interval is 4-9 weeks

Exclusion Criteria

Patients administrated drugs for PV treatment such as hydroxyurea or ruxolitinib (aspirin is excluded)

Study & Design

• Study Type: Interventional
• Study Design: Not specified